Optimizing safety of medicines by pharmacovigilance. What must be done?;Verbesserung der arzneimittelsicherheit durch pharmakovigilanz. Was ist zu tun?

Monatsschrift fur Kinderheilkunde

Volumn 155, Issue 8, 2007, Pages 692-699

  Rascher, W ^a   Mentzer, D ^b   Seyberth, H W ^c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Adverse drug reaction; Children; Drug safety; Pharmacovigilance; Spontaneous reporting

Indexed keywords

CLONIDINE; INSULIN; LAMOTRIGINE; NEUROLEPTIC AGENT; SALBUTAMOL; THALIDOMIDE; THEOPHYLLINE;

CARCINOGENESIS; CHILD SAFETY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; HUMAN; HYPOGLYCEMIA; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA;

EID: 34648837280     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-007-1563-0     Document Type: Review

References (31)

1. American Academy of Pediatrics (2003) Prevention of medication errors in the pediatric inpatient setting. Pediatrics 112: 431-436
2. Arzneimittelkommission der Deutschen Ärzteschaft (2005) Pharmakovigilanz: Empfehlungen zur Meldung unerwünschter Arzneimittelwirkungen durch die Ärzteschaft. Arzneimittelverord Prax 32: 1-30
3. Arzneimittelkommission der Deutschen Ärzteschaft und Kommission Arzneimittelsicherheit der Deutschen Gesellschaft für Kinder- und Jugendmedizin (2007) Leitfaden zur Meldung unerwünschter Arzneimittelwirkungen bei Kindern. Monatsschr Kinderheilk 155: 457-458
4. Bates DW (1996) Medication errors. How common are they and what can be done to prevent them? Drug Saf 15: 303-310
5. Budnitz DS, Pollock DA, Weidenbach KN et al. (2006) National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296: 1858-1866
6. Conroy S, Choonara I, Impicciatore P et al. (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320: 79-82
7. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356: 1255-1259
8. EMEA (1995) ICH Topic E2A: clinical safety data management: definitions and standards for expedited reporting. CPMP/ICH/377/95. EMEA, London
9. EMEA (2007) Guideline on conduct of pharmacovigilance for medicines used by the paediatric population, 25.01.2007. EMEA/CHMP/PhV/235910/2005-rev.1, EMEA, London
10. EU (2006) Verordnung (EG) Nr. 1901/2006. Amtsblatt der Europäischen Union, 27.12.2006, L378/1-19
11. Ernst E (2003) Serious adverse effects of unconventional therapies for children and adolescents: a systematic review of recent evidence. Eur J Pediatr 162: 72-80
12. Gershanik J, Boecler B, Ensley H et al. (1982) The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 307: 1384-1388
13. Göttler M, Munter KH, Hasford J et al. (1999) Zu viele Ärzte sind.,meldemüde". Dtsch Arztebl 96: A1704-A1706
14. Haffner S, Laue N von, Wirth S et al. (2005) Detecting adverse drug reactions on paediatric wards: intensified surveillance versus computerised screening of laboratory values. Drug Saf 28: 453-464
15. Horen B, Montastruc JL, Lapeyre-Mestre M (2002) Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 54: 665-670
16. Kaushal R, Bates DV, Landrigan C et al. (2001) Medication errors and adverse drug events in pediatric inpatients. JAMA 285: 2114-2120
17. Laurence DR (1973) The thalidomide disaster. Clinical Pharmacoly, 4th edn. Churchill Livingstone, Edinburgh London New York, 6.67-6.70
18. Müller-Oerlinghausen B, Munter KH (1997) Die Arzneimittelkommission der deutschen Ärzteschaft - Qualitätssicherung in der Arzneitherapie. Dtsch Arztebl 94: A-2558-A2563
19. Naranjo CA, Busto U, Sellers EM et al. (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245
20. Nebeker JR, Barach P, Samore MH (2004) Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 140: 795-801
21. Neubert A, Dormann H, Weiss J et al. (2004) The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 27: 1059-1067
22. Neubert A, Dormann H, Weiss J et al. (2006) Are computerised monitoring systems of value to improve pharmacovigilance in paediatric patients? Eur J Clin Pharmacol 62: 959-965
23. Pirmohamed M, Breckenridge AM, Kitteringham NR et al. (1998) Adverse drug reactions. BMJ 316: 1295-1298
24. Rascher W, Mentzer D, Seyberth HW (2006) Änderung der Arzneimittelgesetzgebung in Europa - Was hat sich geändert, was wird sich ändern? Monatsschr Kinderheilk 154: 822-824
25. Thürmann PA, Schmitt K (1998) Erfassung und Bewertung unerwünschter Arzneimittelwirkungen. Med Klin 93: 687-692
26. Turner S, Nunn AJ, Fielding K et al. (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 88: 965-968
27. Vincer MJ, Murray JM, Yuill A et al. (1989) Drug errors and incidents in a neonatal intensive care unit. Am J Dis Child 143: 737-740
28. Weiss J, Krebs S, Hoffmann C et al. (2002) Survey of adverse drug reactions on a pediatric ward: a strategy for early and detailed detection. Pediatrics 110: 254-257
29. WHO (1969) International drug monitoring. The role of the hospital. Report of a WHO meeting. World Health Organ Tech Rep Ser 425: 1-24
30. Wang JK, Herzog NS, Kaushal R et al. (2007) Prevention of pediatric medication errors by hospital pharmacists and the potential benefit of computerized physician order entry. Pediatrics 119: 431-436
31. Wong IC, Ghaleb MA, Franklin BD et al. (2004) Incidence and nature of dosing errors in paediatric medications: a systematic review. Drug Saf 27: 661-670